Skip to content

US · VCEL · BIOTECHNOLOGY

Vericel Corporation (VCEL) intrinsic value and stock valuation

$57.52as of 2026-11-21 · Mkt cap 2.32B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Vericel Corporation DCF and intrinsic value

InvestorsCraft values VCEL with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from VCEL’s statements →

Vericel Corporation Graham Number

Graham Number: $7.18d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02139 vcel.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$276.3M+17.3% 5y CAGRd
20112025
Net income
$16.5M+42% 5y CAGRd
20112025
Free cash flow
$24.8M+10.6% 5y CAGRd
20112025
Total equity
$354.6M+21.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$276.3M$237.2M$197.5M$164.4M$156.2M
Operating income$11M$4.52M-$-6.46M-$-17.06M-$-7.85M
Net income$16.5M$10.4M-$-3.18M-$-16.71M-$-7.47M
EPSd$317.3K$200.5K-$-66.82K-$-354.55K-$-160.75K
Operating cash flow$51.9M$58.2M$35.3M$17.7M$29M
Capital expenditure-$-27.16M-$-63.97M-$-27.51M-$-7.6M-$-7.92M
Free cash flow$24.8M-$-5.81M$7.8M$10.1M$21.1M
Total assets$488M$432.7M$353.7M$273M$243.7M
Total debt$98.3M$98.9M$88M$47.6M$50.2M
Net debt-$-1.83M$24.3M$19M-$-3.5M-$-18.15M
Total equity$354.6M$292M$226M$192.3M$170.5M
Cash and short-term investments$137.5M$116.2M$109.6M$119.5M$103.4M
Income statement
20252024202320222021
Revenue$276.3M$237.2M$197.5M$164.4M$156.2M
Cost of revenue$70.7M$65.1M$61.9M$54.6M$50.2M
Gross profit$205.6M$172.1M$135.6M$109.8M$106M
Research and development expenses$27.6M$24.8M$21M$19.9M$16.3M
Selling, general and administrative expenses$167M$142.8M$121M$106.9M$97.6M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$194.6M$167.6M$142M$126.9M$113.9M
Cost and expenses$265.2M$232.7M$204M$181.4M$164M
Interest income$7.01M$6.41M$4.63M$1.34M$220K
Interest expense$1.56M$610K$600K$370K$0.00
Depreciation and amortization$11.4M$5.5M$4.63M$3.98M$2.96M
Ebitda$30.3M$16.6M$2.86M-$-11.64M-$-4.61M
Operating income$11M$4.52M-$-6.46M-$-17.06M-$-7.85M
Total other income/expenses, net$6.33M$5.99M$4.1M$1.07M$270K
Income before tax$17.4M$10.5M-$-2.37M-$-15.99M-$-7.58M
Income tax expense$860K$150K$810K$720K-$-110K
Net income$16.5M$10.4M-$-3.18M-$-16.71M-$-7.47M
Weighted average shares outstanding$50.6M$48.9M$47.6M$47.1M$46.5M
Weighted average diluted shares outstanding$52.1M$51.7M$47.6M$47.1M$46.5M
Balance sheet
20252024202320222021
Cash and short-term investments$137.5M$116.2M$109.6M$119.5M$103.4M
Net receivables$84.6M$61.4M$58.4M$46.5M$37.4M
Inventory$17.6M$17.4M$13.1M$16M$13.4M
Total current assets$247.4M$212.8M$205.6M$186.9M$158.5M
Property, plant and equipment, net$173.2M$173.3M$115.1M$57.4M$59M
Goodwill and intangible assets$5.62M$6.25M$6.88M$7.5M$0.00
Long-term investments$61.4M$39.9M$25.3M$20M$25.7M
Total non-current assets$240.5M$219.9M$148M$86.1M$85.2M
Total assets$488M$432.7M$353.7M$273M$243.7M
Accounts payable$15.8M$23.9M$22.4M$16.9M$9.02M
Short-term debt$14.1M$9.26M$6.19M$4.3M$2.99M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$49.2M$50.3M$45.8M$37.5M$26.1M
Long-term debt$84.2M$89.6M$81.9M$43.3M$47.2M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$84.2M$90.5M$82M$43.3M$47.2M
Capital lease obligations$84.2M$98.9M$88M$47.6M$50.2M
Total liabilities$133.3M$140.8M$127.7M$80.7M$73.2M
Common stock$730.7M$684.8M$629.2M$593.3M$553.9M
Retained earnings-$-376.3M-$-392.81M-$-403.18M-$-400M-$-383.29M
Accumulated other comprehensive income (loss)$280K$0.00-$-100K-$-980K-$-150K
Total equity$354.6M$292M$226M$192.3M$170.5M
Total investments$98.8M$81.6M$65.8M$88.4M$60.8M
Total debt$98.3M$98.9M$88M$47.6M$50.2M
Net debt-$-1.83M$24.3M$19M-$-3.5M-$-18.15M
Cash flow statement
20252024202320222021
Net income$16.5M$10.4M-$-3.18M-$-16.71M-$-7.47M
Depreciation and amortization$11.4M$5.5M$4.63M$3.98M$2.96M
Stock-based compensation$38.8M$36.5M$32.3M$37.2M$34.3M
Change in working capital-$-21.36M-$-450K-$-3.96M-$-11.21M-$-6.15M
Accounts receivable-$-23.26M-$-3.02M-$-11.82M-$-9.1M-$-2.93M
Inventory-$-1.23M-$-4.29M$2.9M-$-2.6M-$-4.03M
Accounts payable$2.97M-$-290K$3.05M$1.44M$1.49M
Net cash provided by operating activities$51.9M$58.2M$35.3M$17.7M$29M
Investments in property, plant and equipment-$-27.16M$0.00$0.00-$-7.6M-$-7.92M
Acquisitions, net$0.00$0.00$0.00$7.6M$7.92M
Net cash used for investing activities-$-43.94M-$-79.03M-$-3.13M-$-36.21M-$-3.5M
Common stock issued$13.9M$24.5M$6M$3.65M$11.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$7.07M$19.1M$3.62M$1.04M$9.17M
Net change in cash$15M-$-1.82M$35.8M-$-17.47M$34.7M
Cash at end of period$100.1M$85.1M$86.9M$51.1M$68.5M
Operating cash flow$51.9M$58.2M$35.3M$17.7M$29M
Capital expenditure-$-27.16M-$-63.97M-$-27.51M-$-7.6M-$-7.92M
Free cash flow$24.8M-$-5.81M$7.8M$10.1M$21.1M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Vericel Corporation

        Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.

        CEO
        Dominick C. Colangelo
        Employees
        398
        Beta
        1.07

        Explore

        Frequently asked questions

        What is the intrinsic value of Vericel Corporation (VCEL)?

        Vericel Corporation (VCEL) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is VCEL undervalued?

        VCEL trades at a price of $57.52 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.